Randomized trial of tofacitinib in active ulcerative colitis: Analysis of efficacy based on patientreported outcomes

BMC Gastroenterology

Volumn 15, Issue 1, 2015, Pages

  Panés, Julián ^a   Su, Chinyu ^b   Bushmakin, Andrew G ^b   Cappelleri, Joseph C ^b   Mamolo, Carla ^b   Healey, Paul ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b PFIZER INC   (United States)

Author keywords

Patient reported outcomes; Quality of life; Tofacitinib; Ulcerative colitis

Indexed keywords

PLACEBO; TOFACITINIB; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; HUMAN; INFLAMMATORY BOWEL DISEASE PATIENT REPORTED TREATMENT IMPACT; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; MAJOR CLINICAL STUDY; MAYO SCORE; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SHORT COURSE THERAPY; SIGMOIDOSCOPY; ULCERATIVE COLITIS; CLINICAL TRIAL; COLITIS, ULCERATIVE; COLONOSCOPY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; SELF REPORT; SEVERITY OF ILLNESS INDEX;

COLITIS, ULCERATIVE; COLONOSCOPY; HUMANS; PATIENT PREFERENCE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; QUALITY OF LIFE; REMISSION INDUCTION; SELF REPORT; SEVERITY OF ILLNESS INDEX;

EID: 84923919260     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-015-0239-9     Document Type: Article

References (22)

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.
2. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228-35.
3. Meyer D, Head R, Thompson J, Ghosh S, LaBranche T, Storer C, et al. Mechanism of action of the JAK inhibitor, CP-690550, in rheumatoid arthritis. 8th Cytokines and Inflammation Conference, San Diego, California, 2010.
4. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53:8468-84.
5. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234-43.
6. Sewgobind VD, Quaedackers ME, van der Laan LJ, Kraaijeveld R, Korevaar SS, Chan G, et al. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. Am J Transplant. 2010;10:1785-95.
7. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Study A3921063 Investigators: Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-24.
8. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.
9. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-96.
10. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992;14:15-9.
11. Jennings AM, Lewis KS, Murdoch S, Talbot JF, Bradley C, Ward JD. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care. 1991;14:738-44.
12. Bradley C. Handbook of psychology and diabetes. In: Bradley C, editor. Diabetes treatment satisfaction questionnaire: DTSQ. Chur: Harwood Academic Publishers; 1994.
13. Giuliano FA, Lamb J, Crossland A, Haughie S, Ellis P, Tamimi NA. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int. 2010;106:666-73.
14. Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int. 2010;106:674-80.
15. Fairclough DL. Design and analysis of quality of life studies in clinical trials. 2nd ed. London: Chapman and Hall/CRC; 2010.
16. Fitzmaurice G, Laird N, Ware J. Applied Longitudinal Analysis. Somerset, NJ: Wiley-Blackwell 2011.
17. Strand V, Fleischmann R, Alten R, Koncz T, Zwillich SH, Bradley JD, et al. Effects of the oral JAK inhibitor tofacitinib monotherapy versus methotrexate on patient reported outcomes in the phase 3 oral START trial of active rheumatoid arthritis [abstract]. Ann Rheum Dis. 2013;72:252.
18. Hall S, Nash P, Rischmueller M, Bossingham D, Cook N, Witcombe D, et al. Tofacitinib, an oral Janus kinase inhibitor: patient reported outcomes in an Australian Phase 3 rheumatoid arthritis study population. 54th Annual Scientific Meeting Australian Rheumatology Association 2013.
19. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2013; doi: 10.1111/jdv.12081.Epub ahead of print.
20. Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11:24-34.
21. Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-86.
22. Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol. 2009;21:558-64.